Oakworth Capital’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.6K | Hold |
50
| – | – | ﹤0.01% | 691 |
|
|
2026
Q1 | $9.8K | Hold |
50
| – | – | ﹤0.01% | 660 |
|
|
2025
Q4 | $8.68K | Hold |
50
| – | – | ﹤0.01% | 673 |
|
|
2025
Q3 | $9.53K | Hold |
50
| – | – | ﹤0.01% | 633 |
|
|
2025
Q2 | $8.98K | Hold |
50
| – | – | ﹤0.01% | 498 |
|
|
2025
Q1 | $8.46K | Hold |
50
| – | – | ﹤0.01% | 530 |
|
|
2024
Q4 | $7.54K | Sell |
50
-33
| -40% | -$5.13K | ﹤0.01% | 519 |
|
|
2024
Q3 | $12.9K | Hold |
83
| – | – | ﹤0.01% | 487 |
|
|
2024
Q2 | $11.4K | Hold |
83
| – | – | ﹤0.01% | 476 |
|
|
2024
Q1 | $11K | Hold |
83
| – | – | ﹤0.01% | 467 |
|
|
2023
Q4 | $11.4K | Hold |
83
| – | – | ﹤0.01% | 461 |
|
|
2023
Q3 | $10.1K | Hold |
83
| – | – | ﹤0.01% | 445 |
|
|
2023
Q2 | $11.7K | Hold |
83
| – | – | ﹤0.01% | 443 |
|
|
2023
Q1 | $11.7K | Hold |
83
| – | – | ﹤0.01% | 422 |
|
|
2022
Q4 | $13K | Hold |
83
| – | – | ﹤0.01% | 391 |
|
|
2022
Q3 | $10K | Hold |
83
| – | – | ﹤0.01% | 445 |
|
|
2022
Q2 | $11K | Hold |
83
| – | – | ﹤0.01% | 430 |
|
|
2022
Q1 | $11K | Hold |
83
| – | – | ﹤0.01% | 438 |
|
|
2021
Q4 | $14K | Sell |
83
-17
| -17% | -$2.59K | ﹤0.01% | 455 |
|
|
2021
Q3 | $15K | Sell |
100
-100
| -50% | -$14.6K | ﹤0.01% | 435 |
|
|
2021
Q2 | $26K | Sell |
200
-184
| -48% | -$24.1K | ﹤0.01% | 387 |
|
|
2021
Q1 | $49K | Hold |
384
| – | – | 0.01% | 308 |
|
|
2020
Q4 | $46K | Hold |
384
| – | – | 0.01% | 291 |
|
|
2020
Q3 | $44K | Sell |
384
-9
| -2% | -$1.06K | 0.01% | 289 |
|
|
2020
Q2 | $45K | Hold |
393
| – | – | 0.01% | 283 |
|
|
2020
Q1 | $32K | Hold |
393
| – | – | 0.01% | 288 |
|
|
2019
Q4 | $41K | Hold |
393
| – | – | 0.01% | 306 |
|
|
2019
Q3 | $42K | Sell |
393
-1,695
| -81% | -$174K | 0.01% | 308 |
|
|
2019
Q2 | $212K | Hold |
2,088
| – | – | 0.04% | 163 |
|
|
2019
Q1 | $187K | Sell |
2,088
-230
| -10% | -$19.9K | 0.04% | 178 |
|
|
2018
Q4 | $193K | Sell |
2,318
-290
| -11% | -$27.2K | 0.04% | 157 |
|
|
2018
Q3 | $281K | Hold |
2,608
| – | – | 0.06% | 140 |
|
|
2018
Q2 | $286K | Hold |
2,608
| – | – | 0.06% | 130 |
|
|
2018
Q1 | $264K | Hold |
2,608
| – | – | 0.06% | 132 |
|
|
2017
Q4 | $257K | Hold |
2,608
| – | – | 0.06% | 133 |
|
|
2017
Q3 | $283K | Hold |
2,608
| – | – | 0.07% | 123 |
|
|
2017
Q2 | $290K | Hold |
2,608
| – | – | 0.08% | 114 |
|
|
2017
Q1 | $257K | Hold |
2,608
| – | – | 0.07% | 128 |
|
|
2016
Q4 | $228K | Hold |
2,608
| – | – | 0.08% | 138 |
|
|
2016
Q3 | $221K | Hold |
2,608
| – | – | 0.08% | 133 |
|
|
2016
Q2 | $201K | Buy |
2,608
+1,594
| +157% | +$121K | 0.08% | 139 |
|
|
2016
Q1 | $72K | Buy |
1,014
+750
| +284% | +$50.3K | 0.03% | 184 |
|
|
2015
Q4 | $19K | Hold |
264
| – | – | 0.01% | 299 |
|
|
2015
Q3 | $16K | Hold |
264
| – | – | 0.01% | 264 |
|
|
2015
Q2 | $19K | Sell |
264
-2,000
| -88% | -$148K | 0.01% | 260 |
|
|
2015
Q1 | $162K | Hold |
2,264
| – | – | 0.07% | 125 |
|
|
2014
Q4 | $152K | Buy |
2,264
+2,000
| +758% | +$126K | 0.08% | 128 |
|
|
2014
Q3 | $17K | Hold |
264
| – | – | 0.01% | 244 |
|
|
2014
Q2 | $15K | Hold |
264
| – | – | 0.01% | 255 |
|
|
2014
Q1 | $15K | Hold |
264
| – | – | 0.01% | 251 |
|
|
2013
Q4 | $14K | Buy |
+264
| New | +$15.7K | 0.01% | 238 |
|
Other funds holding DGX
AIM
EB
CPC
AIM
AAMU
AAIS
SIC
BCAM
Oakworth Capital's DGX Position: Q2 2026 in Review
Oakworth Capital held its Quest Diagnostics (DGX) position steady in Q2 2026 at 50 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #691.
Oakworth Capital first reported a position in DGX in Q4 2013 and has held it in 51 quarters since. The position peaked at $290K in Q2 2017. 308 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Oakworth Capital held 50 shares of Quest Diagnostics worth $10.6K as of Q2 2026.
- Oakworth Capital left its Quest Diagnostics share count unchanged in Q2 2026.
- Quest Diagnostics made up ﹤0.01% of Oakworth Capital's portfolio in Q2 2026, its #691 holding.
- Oakworth Capital first reported a position in Quest Diagnostics in Q4 2013 and has held it in 51 quarters since.
- Oakworth Capital's Quest Diagnostics position peaked at $290K in Q2 2017.
- 308 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Oakworth Capital's 13F filing for Q2 2026, filed 22 Jul 2026.